Actively Recruiting
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours
Led by Grit Biotechnology · Updated on 2026-04-14
18
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
CONDITIONS
Official Title
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily join the study, signed informed consent form, willing and able to comply with the study protocol
- Age 18 to 70 years old
- Ovarian cancer that progresses after recurrence or first-line chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Expected survival time of 6 12 weeks
- Good function of vital organs
- Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling
- At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling
You will not qualify if you...
- Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry
- Known mental illness, alcoholism, drug use or substance abuse
- Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion
- Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion, plan to participate in other clinical trial drug treatment during the study
- The investigators determine that other conditions that make the patient not suitable for enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 200011
Actively Recruiting
Research Team
K
Kang Yu, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here